Accessibility Menu
Xvivo Perfusion Ab (publ) logo

Xvivo Perfusion Ab (publ)(OTC) XVIPF

Current Price$24.50
Market Cap$771.74MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)+314%
5 Year-46%
1 Year+11%
1 Month-16%
Xvivo Perfusion Ab (publ) last closing stock price
MetricPriceDate
Last closeUSD 24.502026-07-21
Xvivo Perfusion Ab (publ) stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-16.89%USD 29.482026-07-09
1 month-15.52%USD 29.002026-06-12
3 month+7.41%USD 22.812026-03-30
Year to date+18.36%USD 20.702025-12-30
1 year+11.36%USD 22.002025-07-18
3 year-16.81%USD 29.452023-07-13
5 year-46.04%USD 45.402021-07-22
Since inception+313.85%USD 5.922014-07-23

Xvivo Perfusion Ab (publ) Financials at a Glance

Market Cap

$771.74MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

SEK 891.31M

Net Income (TTM)

SEK 88.32M

EPS (TTM)

$0.30

P/E Ratio

80.96

Dividend

$0.00

Beta (Volatility)

0.28 (Low)

Price

$24.50

Volume

1,000

Open

$24.50

Previous Close

$24.50

Daily Range

$24.50 - $24.50

52-Week Range

$16.98 - $29.48

Estimated Earnings Date

Oct 22, 2026

XVIPF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Xvivo Perfusion Ab (publ)

Xvivo Perfusion AB (publ) is a medical technology company focused on enhancing transplantation medicine. The firm specializes in innovative solutions for the preservation and perfusion of organs, tissues, and cells, which are vital for successful transplant procedures.

Products and Services
  • XVIVO System (XPS) for normothermic ex vivo lung perfusion
  • XPS Disposable Lung Kit for essential EVLP components
  • STEEN Solution, a buffered extracellular fluid for lung perfusion
Growth Outlook
  • Revenue of 240.96 million SEK in Q1 2026, a significant increase
  • Gross profit margin improved to 70.98% in Q1 2026
  • Strong international presence across multiple markets enhances growth potential
Financial Highlights
  • Net income of 36.30 million SEK in Q1 2026, reflecting profitability
  • Current ratio of 4.52 indicates strong liquidity position
  • Operating income margin of 13.26% showcases operational efficiency
Xvivo Perfusion AB (publ) has established itself as a leader in the medical devices sector, particularly in transplantation medicine. The company's innovative products, such as the XVIVO System and STEEN Solution, are designed to improve the success rates of organ transplants, addressing a critical need in healthcare. The growth outlook appears promising, with a notable increase in revenue and gross profit margins, indicating effective management and operational strategies. The company's strong liquidity position, as evidenced by a current ratio of 4.52, suggests it is well-equipped to meet short-term obligations and invest in future growth opportunities. Recent financial performance highlights, including a net income of 36.30 million SEK in Q1 2026, further underscore the company's profitability and operational efficiency. With a robust international presence and a commitment to innovation, Xvivo Perfusion AB (publ) is well-positioned for continued growth in the evolving medical technology landscape.
AI Generated • Jul 7, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

197

CEO

Christoffer Rosenblad, MBA

Website

www.xvivogroup.com

Headquarters

Mölndal, VG SE-431 53, SE

XVIPF Financials

Key Financial Metrics (TTM)

Gross Margin

62.85%

Operating Margin

12.66%

Net Income Margin

9.89%

Return on Equity

4.13%

Return on Capital

4.16%

Return on Assets

3.51%

Earnings Yield

1.24%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$771.74MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

31.50M

Volume

1.00K

Avg. Volume

56.307

Financials (TTM)

Gross Profit

SEK 591.91M

Operating Income

SEK 109.00M

EBITDA

SEK 183.38M

Operating Cash Flow

SEK 235.45M

Capital Expenditure

-SEK 180.06M

Free Cash Flow

SEK 141.87M

Cash & ST Invst.

SEK 31.32M

Total Debt

SEK 12.49M

Xvivo Perfusion Ab (publ) Performance Analysis

Xvivo Perfusion Ab (publ) annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31SEK 41,037,19136.3%
20232023-12-31SEK 56,287,22237.2%
20242024-12-31SEK 77,786,43138.2%
20252025-12-31SEK 82,810,5296.5%
Xvivo Perfusion Ab (publ) sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-305.4%
Q42025-12-3120.1%
Q12026-03-316.8%
Q22026-06-30-1.7%
Xvivo Perfusion Ab (publ) annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31SEK 0.0688.1%
20232023-12-31SEK 0.29368.2%
20242024-12-31SEK 0.5178.1%
20252025-12-31SEK 0.08-84.2%
Xvivo Perfusion Ab (publ) sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30180.0%
Q42025-12-31614.3%
Q12026-03-3115.0%
Q22026-06-30-55.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

SEK 236.94M

+32.9%

Gross Profit

SEK 149.83M

+12.9%

Gross Margin

63.23%

N/A

Market Cap

$771.74MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.88M

N/A

Employees

199

N/A

Net Income

SEK 16.14M

+926.2%

EBITDA

SEK 41.63M

+487.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

SEK 31.32M

-90.3%

Total Debt

SEK 12.49M

+7.1%

Accounts Receivable

SEK 20.13M

-88.9%

Inventory

SEK 23.40M

-91.3%

Long Term Debt

SEK 11.29M

-89.0%

Short Term Debt

SEK 1.20M

+46.0%

Return on Assets

3.51%

N/A

Return on Invested Capital

4.85%

N/A

Free Cash Flow

SEK 0.00

-100.0%

Operating Cash Flow

SEK 62.95M

+615.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AVNBFAvon Technologies Plc
$22.49+0.00%
SOLTFNxera Pharma Co., Ltd.
$5.63+0.00%
CALZFPolynovo Limited
$0.59-2.14%
VBIZFViva Biotech Holdings
$0.16+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
SOFISoFi Technologies
$16.46-0.01%

Questions About XVIPF

What is the current price of Xvivo Perfusion Ab (publ)?

Xvivo Perfusion Ab (publ) is trading at $24.50 per share.

What is the 52-week range for Xvivo Perfusion Ab (publ)?

Over the past 52 weeks, Xvivo Perfusion Ab (publ) has traded between $16.98 and $29.48.

How much debt does Xvivo Perfusion Ab (publ) have?

As of the most recent reporting period, Xvivo Perfusion Ab (publ) reported total debt of SEK 12.57M.

How much cash does Xvivo Perfusion Ab (publ) have on hand?

Xvivo Perfusion Ab (publ) reported SEK 31.51M in cash and cash equivalents in its most recent financial results.

What is Xvivo Perfusion Ab (publ)’s dividend yield?

Xvivo Perfusion Ab (publ) does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services